Marjan Mujib1, Neel Khanna2, Nabila K Mazumder3, Wilbert S Aronow2, Dhaval Kolte1, Sahil Khera2, Chandrasekar Palaniswamy4, Diwakar Jain2, Gregg M Lanier2, Sachin Sule1, Ali Ahmed5, Wayne C Levy6, Sumanth D Prabhu7, Howard A Cooper2, Julio A Panza2, Alan L Gass2, Gregg C Fonarow8. 1. Department of Medicine, New York Medical College, Valhalla, New York. 2. Division of Cardiology, New York Medical College, Valhalla, New York. 3. Department of Medicine, Flushing Hospital Medical Center, Flushing, New York. 4. Department of Medicine, Division of Cardiology, Mount Sinai Medical Center, New York, New York. 5. Department of Medicine, Washington DC VA Medical Center, Washington, DC. 6. Division of Cardiology, University of Washington, Seattle, Washington. 7. Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama. 8. Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: The prevalence and contemporary trends of pre-heart transplantation (HT) coagulopathy and associated clinical outcomes have not been studied from a national database. HYPOTHESIS: Pre-HT coagulopathy is associated with increased in-hospital mortality. METHODS: Among 2454 adult HT recipients from the 2003 to 2010 Nationwide Inpatient Sample databases, 707 (29%) had pre-HT coagulopathy (defined as a comorbidity variable, based on International Classification of Diseases, Ninthe Revision, Clinical Modification and Diagnosis Related Group codes). We used propensity scores for coagulopathy to assemble a matched cohort of 664 pairs of patients with and without coagulopathy balanced in 54 baseline characteristics. RESULTS: The prevalence of pre-HT coagulopathy increased from 17% in 2003 to 44% in 2010 (P for trend <0.001). In-hospital mortality occurred in 8.6% and 4.7% of matched HT recipients with and without coagulopathy, respectively (hazard ratio: 1.81; 95% confidence interval [CI]: 1.17-2.80; P = 0.008). Coagulopathy was not significantly associated with post-HT graft complications (odds ratio [OR]: 1.20; 95% CI: 0.95-1.52; P = 0.131) but was associated with increased blood transfusions (OR: 1.92; 95% CI, 1.54-2.41; P < 0.001). Coagulopathy and no-coagulopathy groups had no difference in median length of stay (22 days in each group, P = 0.746), but median total hospital charges were higher among patients with coagulopathy compared to those without (US$425 643 vs US$389 656; P = 0.008). CONCLUSIONS: In this national study of HT recipients, pretransplant coagulopathy was common, increased over time, and was not significantly associated with post-HT graft complications or increased hospital stay. However, it was associated with increased bleeding risk, in-hospital mortality, and total hospital charges. These findings may have implications for the selection of patients for HT.
BACKGROUND: The prevalence and contemporary trends of pre-heart transplantation (HT) coagulopathy and associated clinical outcomes have not been studied from a national database. HYPOTHESIS: Pre-HT coagulopathy is associated with increased in-hospital mortality. METHODS: Among 2454 adult HT recipients from the 2003 to 2010 Nationwide Inpatient Sample databases, 707 (29%) had pre-HT coagulopathy (defined as a comorbidity variable, based on International Classification of Diseases, Ninthe Revision, Clinical Modification and Diagnosis Related Group codes). We used propensity scores for coagulopathy to assemble a matched cohort of 664 pairs of patients with and without coagulopathy balanced in 54 baseline characteristics. RESULTS: The prevalence of pre-HT coagulopathy increased from 17% in 2003 to 44% in 2010 (P for trend <0.001). In-hospital mortality occurred in 8.6% and 4.7% of matched HT recipients with and without coagulopathy, respectively (hazard ratio: 1.81; 95% confidence interval [CI]: 1.17-2.80; P = 0.008). Coagulopathy was not significantly associated with post-HT graft complications (odds ratio [OR]: 1.20; 95% CI: 0.95-1.52; P = 0.131) but was associated with increased blood transfusions (OR: 1.92; 95% CI, 1.54-2.41; P < 0.001). Coagulopathy and no-coagulopathy groups had no difference in median length of stay (22 days in each group, P = 0.746), but median total hospital charges were higher among patients with coagulopathy compared to those without (US$425 643 vs US$389 656; P = 0.008). CONCLUSIONS: In this national study of HT recipients, pretransplant coagulopathy was common, increased over time, and was not significantly associated with post-HT graft complications or increased hospital stay. However, it was associated with increased bleeding risk, in-hospital mortality, and total hospital charges. These findings may have implications for the selection of patients for HT.
Authors: Damien J LaPar; Castigliano M Bhamidipati; Carlos M Mery; George J Stukenborg; David R Jones; Bruce D Schirmer; Irving L Kron; Gorav Ailawadi Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Yasmin Wadia; Whitson Etheridge; Frank Smart; R Patrick Wood; O H Frazier Journal: J Heart Lung Transplant Date: 2005-04 Impact factor: 10.247
Authors: Anna L Meyer; Doris Malehsa; Christoph Bara; Ulrich Budde; Mark S Slaughter; Axel Haverich; Martin Strueber Journal: Circ Heart Fail Date: 2010-08-25 Impact factor: 8.790
Authors: Justin M Bachmann; Ashish S Shah; Meredith S Duncan; Robert A Greevy; Amy J Graves; Shenghua Ni; Henry H Ooi; Thomas J Wang; Randal J Thomas; Mary A Whooley; Matthew S Freiberg Journal: J Heart Lung Transplant Date: 2017-05-23 Impact factor: 10.247
Authors: Santosh B Murthy; Aditi Shastri; Alexander E Merkler; Daniel F Hanley; Wendy C Ziai; Matthew E Fink; Costantino Iadecola; Hooman Kamel; Babak B Navi Journal: J Stroke Cerebrovasc Dis Date: 2016-08-25 Impact factor: 2.136
Authors: Justin M Bachmann; Meredith S Duncan; Ashish S Shah; Robert A Greevy; JoAnn Lindenfeld; Steven J Keteyian; Randal J Thomas; Mary A Whooley; Thomas J Wang; Matthew S Freiberg Journal: JACC Heart Fail Date: 2018-02 Impact factor: 12.035